A few years ago, Roche abandoned the development of its lead PIK3CA-targeting drug taselisib on safety grounds, allowing rival Novartis to beat it to market, but now it ha
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<